SWM
ALGS icon

Spire Wealth Management’s Aligos Therapeutics ALGS Stock Holding History

Spire Wealth Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$7.97K – 2465
2024
Q4 		$7.97K Buy
+200
New +$3.87K ﹤0.01% 1904

Other funds holding ALGS

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Spire Wealth Management's ALGS Position: Q1 2025 in Review

Spire Wealth Management sold out of Aligos Therapeutics (ALGS) in Q1 2025, closing a stake of 200 shares — an estimated $7.97K sold.

Spire Wealth Management first reported a position in ALGS in Q4 2024 and held it in 1 quarter. The position peaked at $7.97K in Q4 2024. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2025.

  • Spire Wealth Management reported no remaining Aligos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Spire Wealth Management sold 200 Aligos Therapeutics shares in Q1 2025, an estimated $7.97K.
  • Spire Wealth Management first reported a position in Aligos Therapeutics in Q4 2024 and held it in 1 quarter.
  • Spire Wealth Management's Aligos Therapeutics position peaked at $7.97K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2025.

Based on Spire Wealth Management's 13F filing for Q1 2025, filed 23 Apr 2025.